LOGIN  |  REGISTER
Astria Therapeutics

Astrana Health Announces Share Repurchase of 300,000 Shares

January 21, 2025 | Last Trade: US$24.90 0.71 -2.77

ALHAMBRA, Calif., Jan. 21, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that on January 17, 2025, the Company repurchased 300,000 shares of the Company's common stock for the aggregate purchase price of $10.551 million, based on a purchase price per share of $35.17, which was the closing price per share on the Nasdaq Stock Market on such date.

"The share repurchase is a testament to management and the Board of Directors' confidence in the performance of Astrana Health. We remain committed to our strategic capital deployment practices and continue to prioritize long-term growth, including through opportunistic share repurchases," said Brandon K. Sim, President and CEO of Astrana.

The shares were purchased from Allied Physicians of California, a Professional Medical Corporation ("APC"), a long-standing stockholder and a consolidated affiliate of the Company. The Company's Board of Directors and the Audit Committee of the Board of Directors approved the repurchase.

About Astrana Health, Inc.

Astrana is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, Astrana serves over 12,000 providers and over 1.1 million Americans in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), accountable care organizations (ACOs), and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
Asher Dewhurst
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page